Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation

Anti-CTLA-4 relies on RIG-I for tumor control

Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy

Anti-CTLA-4 therapy for malignant mesothelioma

CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation

A Novel CTLA-4 affinity peptide for cancer immunotherapy by increasing the integrin αvβ3 targeting

Cancers, Free Full-Text

Fates of CD8+ T cells in Tumor Microenvironment - Computational and Structural Biotechnology Journal

Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation

Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T- cell responses - ScienceDirect

Recent advances in light-triggered cancer immunotherapy - Journal of Materials Chemistry B (RSC Publishing) DOI:10.1039/D3TB02842A